Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew J Ellis

Showing results (101-110 of 285) with videos related to

Pageof 29
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2004
A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasiaVered Stearns, Andrew Coop, Baljit Singh, et al.
European Journal of Cancer (Oxford, England : 1990)|March 26, 2018
Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancerJohn F R Robertson, Kwok-Leung Cheung, Shinzaburo Noguchi, et al.
Molecular & Cellular Proteomics : MCP|November 25, 2015
QuantFusion: Novel Unified Methodology for Enhanced Coverage and Precision in Quantifying Global Proteomic Changes in Whole TissuesHarsha P Gunawardena, Jonathon O'Brien, John A Wrobel, et al.
Journal of the American Academy of Dermatology|June 6, 2024
De novo belatacept does not reduce the rate of skin cancer in renal transplant recipients compared to standard therapyOlivia S Jew, Winston W Liu, Christopher Stamey, et al.
Breast Cancer Research and Treatment|October 16, 2012
Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' studyJohn F R Robertson, Justin P O Lindemann, Antonio Llombart-Cussac, et al.
Pediatric Pulmonology|July 10, 2022
Feasibility of the A-STEP for the assessment of exercise capacity in people with cystic fibrosisLisa M Wilson, Angela Potter, Carol Maher, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 25, 2013
A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standardJennifer R Won, Dongxia Gao, Christine Chow, et al.
Annals of Surgical Oncology|January 18, 2023
Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast CancerKelly K Hunt, Vera J Suman, Hannah F Wingate, et al.
Cold Spring Harbor Perspectives in Medicine|May 3, 2023
The Breast Cancer Proteome and Precision OncologyJonathan T Lei, Eric J Jaehnig, Hannah Smith, et al.
Nature Communications|May 20, 2021
Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancerNindo B Punturi, Sinem Seker, Vaishnavi Devarakonda, et al.
Pageof 29

Showing results (101-110 of 285) with videos related to

Sort By:
Pageof 29
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2004
A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasiaVered Stearns, Andrew Coop, Baljit Singh, et al.
European Journal of Cancer (Oxford, England : 1990)|March 26, 2018
Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancerJohn F R Robertson, Kwok-Leung Cheung, Shinzaburo Noguchi, et al.
Molecular & Cellular Proteomics : MCP|November 25, 2015
QuantFusion: Novel Unified Methodology for Enhanced Coverage and Precision in Quantifying Global Proteomic Changes in Whole TissuesHarsha P Gunawardena, Jonathon O'Brien, John A Wrobel, et al.
Journal of the American Academy of Dermatology|June 6, 2024
De novo belatacept does not reduce the rate of skin cancer in renal transplant recipients compared to standard therapyOlivia S Jew, Winston W Liu, Christopher Stamey, et al.
Breast Cancer Research and Treatment|October 16, 2012
Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' studyJohn F R Robertson, Justin P O Lindemann, Antonio Llombart-Cussac, et al.
Pediatric Pulmonology|July 10, 2022
Feasibility of the A-STEP for the assessment of exercise capacity in people with cystic fibrosisLisa M Wilson, Angela Potter, Carol Maher, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 25, 2013
A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standardJennifer R Won, Dongxia Gao, Christine Chow, et al.
Annals of Surgical Oncology|January 18, 2023
Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast CancerKelly K Hunt, Vera J Suman, Hannah F Wingate, et al.
Cold Spring Harbor Perspectives in Medicine|May 3, 2023
The Breast Cancer Proteome and Precision OncologyJonathan T Lei, Eric J Jaehnig, Hannah Smith, et al.
Nature Communications|May 20, 2021
Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancerNindo B Punturi, Sinem Seker, Vaishnavi Devarakonda, et al.
Pageof 29